Print

Purpose

The purpose of this study is to measure how well LY3819253 and LY3832479 work against the virus that causes COVID-19. LY3819253 and LY3832479 will be given to participants with early symptoms of COVID-19. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study. Participation could last about 12 weeks and includes one required visit to the study site, with the remainder of assessments performed in the home or by phone. Pediatric participants, with mild to moderate COVID-19 illness, will enroll in a single-arm (Arm 22), open-label addendum to evaluate the pharmacokinetics and safety of LY3819253 and LY3832479. Enrollment began on March 31, 2021, and completed on September 24, 2021. Pediatric participants, with mild to moderate COVID-19 illness, will enroll in a single-arm (Arm 23), open-label addendum to evaluate the pharmacokinetics and safety of LY3853113. Enrollment began on August 19, 2022, and completed on February 21, 2023.

Condition

Eligibility

Eligible Ages
Over 0 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Are currently not hospitalized. (Not applicable to participants in treatment arm 22.) - Have one or more mild or moderate COVID-19 symptoms: Fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, or shortness of breath with exertion. (Not applicable to participants in treatment arm 22.) - Must have sample taken for test confirming viral infection no more than 3 days prior to starting the drug infusion - Are males or females, including pregnant females who agree to contraceptive requirements - Understand and agree to comply with planned study procedures - Agree to the collection of nasopharyngeal swabs and venous blood. (Not applicable to participants in treatment arms 20-21.) - The participant or legally authorized representative give signed informed consent and/or assent Participants in treatment arms 7-9, 13-14, and 18-21 ONLY - Are greater than or equal to (≥)18 years of age and must satisfy at least one of the following at the time of screening - Are pregnant - Are ≥65 years of age - Have a body mass index (BMI) ≥35 - Have chronic kidney disease (CKD) - Have type 1 or type 2 diabetes - Have immunosuppressive disease - Are currently receiving immunosuppressive treatment or - Are ≥55 years of age AND have: - cardiovascular disease (CVD), OR - hypertension, OR - chronic obstructive pulmonary disease (COPD) or other chronic respiratory disease - Are 12-17 years of age (inclusive) AND satisfy at least one of the following at the time of screening - Are pregnant - Have a body mass index (BMI) ≥85th percentile for their age and gender based on CDC growth charts, https://www.cdc.gov/growthcharts/clinical_charts.htm - Have sickle cell disease - Have congenital or acquired heart disease - Have neurodevelopmental disorders, for example, cerebral palsy - Have a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19) - Have asthma or reactive airway or other chronic respiratory disease that requires daily medication for control - Have type 1 or type 2 diabetes - Have chronic kidney disease - Have immunosuppressive disease, or - Are currently receiving immunosuppressive treatment Participants in treatment arm 22 ONLY - Are 0 (≥ 32 weeks gestational age AND ≥ 1.5 kilograms [kg]) to 17 years of age (inclusive) AND satisfy at least one of the following risk factors at the time of screening - Are pregnant - Have a BMI ≥85th percentile for their age and gender based on CDC growth charts, https://www.cdc.gov/growthcharts/clinical_charts.htm - Have sickle cell disease - Have congenital or acquired heart disease - Have neurodevelopmental disorders, for example, cerebral palsy, autism, or Down syndrome (FAIR Health 2020; Spreat et al. 2020) - Have a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19) - Have asthma, cystic fibrosis, reactive airways disease or other chronic respiratory disease that requires daily medication for control - Have type 1 or type 2 diabetes - Have chronic kidney disease - Have immunosuppressive disease, or - Are currently receiving immunosuppressive treatment, or - Are less than (<) one year of age. - Have one or more COVID-19 symptoms - Shortness of breath/difficulty breathing - Fever - Sore throat - Nausea - Diarrhea - Tiredness - Headache - New loss of taste - Nasal congestion/runny nose - Chills - Stomachache - Vomiting - Cough - Muscle/body aches and pain - New loss of smell - Poor appetite or poor feeding (in babies) Participants in treatment arm 23 ONLY: Must have first positive result sample of current SARS-CoV-2 viral infection ≤3 days prior to start of treatment administration. Participant can have COVID previously and still meet criteria for this addendum. Positive result needs to be from a current infection. Are 0 (≥ 38 weeks gestational age and ≥ 3.3 kg) to <12 years of age at the time of screening, or are 12 to 17 and weighing <40 kg; and - Have mild to moderate COVID-19 disease, including one or more COVID-19 symptoms within the last 7 days - Shortness of breath/difficulty breathing - Fever - Sore throat - Nausea - Diarrhea - Tiredness - Headache - New loss of taste - Nasal congestion/runny nose - Chills - Malaise - Vomiting - Cough - Muscle/body aches and pain - New loss of smell - Poor appetite or poor feeding (in babies under 1 year old)

Exclusion Criteria

  • Have oxygen saturation (SpO2) less than or equal to (≤)93 percent (%) on room air at sea level or ratio of arterial oxygen partial pressure (PaO2 in millimeters of mercury) to fractional inspired oxygen (FiO2) less than (<)300, respiratory rate greater than or equal to (≥)30 per minute, heart rate ≥125 per minute due to COVID-19 - Require mechanical ventilation or anticipated impending need for mechanical ventilation due to COVID-19 - Have known allergies to any of the components used in the formulation of the interventions - Have hemodynamic instability requiring use of pressors within 24 hours of randomization - Suspected or proven serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking intervention - Have any co-morbidity requiring surgery within <7 days, or that is considered life-threatening within 29 days - Have any serious concomitant systemic disease, condition or disorder that, in the opinion of the investigator, should preclude participation in this study - Have a history of a positive SARS-CoV-2 test prior to the one serving as eligibility for this study - Have received an investigational intervention for SARS-CoV-2 prophylaxis within 30 days before dosing - Have received treatment with a SARS-CoV-2 specific monoclonal antibody - Have received convalescent COVID-19 plasma treatment - Have participated in a previous SARS-CoV-2 vaccine study or have received a SARS-CoV-2 vaccine - Have participated, within the last 30 days, in a clinical study involving an investigational intervention. If the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed - Are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study - Mothers who are breast feeding Participants in Treatment Arm 22 ONLY - Have a diagnosis of Multisystem Inflammatory Syndrome in Children (MIS-C) in the opinion of the investigator - Are currently hospitalized for treatment of COVID-19. Other reasons for hospitalization are acceptable. Participants in treatment arm 23 ONLY - SpO2 ≤ 93% on room air at sea level, or while on chronic oxygen therapy and/or respiratory support due to underlying non-COVID-19 related comorbidity, respiratory rate ≥30 per minute, and heart rate ≥125 per minute due to COVID-19 (FDA February 2021) - Require mechanical ventilation or anticipated impending need for mechanical ventilation due to COVID-19 - Have known allergies to any of the components used in the formulation of the interventions - Have hemodynamic instability requiring use of pressors within 24 hours of randomization - Suspected or proven serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking intervention - Have any co-morbidity requiring surgery within 7 days, or that is considered life-threatening within 29 days - Have any serious concomitant systemic disease, condition or disorder that, in the opinion of the investigator, should preclude participation in this study. - Have received treatment with a SARS-CoV-2 specific monoclonal antibody or remdesivir within 90 days before dosing. - Have received convalescent COVID-19 plasma treatment within 90 days before dosing - Have participated, within the last 30 days, in a clinical study involving an investigational intervention. If the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed - Are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study - Are currently pregnant or breast feeding

Study Design

Phase
Phase 2/Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Sequential Assignment
Primary Purpose
Treatment
Masking
Double (Participant, Investigator)
Masking Description
Some treatment arms are open label.

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
LY3819253 		700 mg, 2800 mg, 7000 mg, LY3819253 administered intravenously (IV)
  • Drug: LY3819253
    Administered IV
    Other names:
    • LY-CoV555
    • Bamlanivimab
Experimental
LY3819253 + LY3832479 		350 mg, 700 mg, 2800 mg LY3819253 + 700 mg, 1400 mg, 2800 mg LY3832479 administered IV or subcutaneously (SQ)
  • Drug: LY3819253
    Administered IV
    Other names:
    • LY-CoV555
    • Bamlanivimab
  • Drug: LY3832479
    Administered IV
    Other names:
    • LY-CoV016
    • Etesevimab
Experimental
LY3819253 + LY3832479 (Pediatric Addendum, Arm 22) 		LY3819253 dose based upon weight (weight Group: ≥40 kilogram (kg) = 700 mg dose, >20 kg to <40 kg = 350 mg dose, >12 kg to 20 kg = 175 mg dose and 1.5 kg to 12 kg = 15 mg/kg dose) and LY3832479 dose based upon weight (weight Group: ≥40 kg = 1400 mg dose, >20 kg to <40 kg = 700 mg dose, >12 kg to 20 kg = 350 mg dose and 1.5 kg to 12 kg = 30 mg/kg dose) administered IV.
  • Drug: LY3819253
    Administered IV
    Other names:
    • LY-CoV555
    • Bamlanivimab
  • Drug: LY3832479
    Administered IV
    Other names:
    • LY-CoV016
    • Etesevimab
Experimental
LY3853113 (Pediatric Addendum, Arm 23) 		LY3853113 dose based upon weight (Weight Group: ≥3.3 to ≤12 kg = 3 mg/kg dose, >12 to ≤20 kg = 43.75 mg dose, >20 to <40 kg = 87.5 mg dose, ≥40 kg = 175 mg dose) administered IV.
  • Drug: LY3853113
    Administered IV
    Other names:
    • bebtelovimab
Placebo Comparator
Placebo 		Placebo administered IV
  • Drug: Placebo
    Administered IV

More Details

Status
Completed
Sponsor
Eli Lilly and Company

Study Contact

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.